Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT04041310

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Sponsor: Merck Sharp & Dohme LLC

Conditions Solid Tumor, Adult

Interventions GAd-209-FSP high dose GAd-209-FSP low dose GAd20-209-FSP, RP2D KEYTRUDA® MVA-209-FSP high dose MVA-209-FSP low dose MVA-209-FSP, RP2D

Updated 29 times since 2019 Last updated: Feb 10, 2026 Started: Oct 21, 2019 Primary completion: Oct 30, 2026 Completion: Oct 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Solid Tumor, Adult, this trial is ongoing. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 29 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

29 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Dec 2024 — Aug 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 24 earlier versions

Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2022 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Nov 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Active Not Recruiting → Recruiting
Dec 2021 — Mar 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
Nov 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE1

Status: Active Not Recruiting → Recruiting
Sep 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Apr 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Jul 2020 — Oct 2020 [monthly]

Recruiting PHASE1
Jun 2020 — Jul 2020 [monthly]

Recruiting PHASE1
Apr 2020 — Jun 2020 [monthly]

Recruiting PHASE1
Feb 2020 — Apr 2020 [monthly]

Recruiting PHASE1
Dec 2019 — Feb 2020 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Nov 2019 — Dec 2019 [monthly]

Not Yet Recruiting PHASE1
Sep 2019 — Nov 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Nouscom SRL

Data source: Nouscom SRL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Avellino, Italy , Baltimore, United States , Barcelona, Spain , Brussels, Belgium , Buffalo, United States , Candiolo, Italy , Córdoba, Spain , Duarte, United States , Goshen, United States and 22 more locations